Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Treatment of C3 glomerulopathy with complement blockers.

Seminars in thrombosis and hemostasis - 1 Jun 2014

Vivarelli Marina, Emma Francesco

Abstract excerpt

C3 glomerulopathy (C3G) is a newly defined clinical entity comprising glomerular lesions with predominant C3 staining. Under this definition are now included membranoproliferative glomerulonephritis type II (dense deposit disease) and C3 glomerulonephritis. This group of glomerular diseases with a heterogeneous histological aspect shares a common pathogenesis, that is, a dysregulation of the alternative pathway...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Complement Activation
Share to Complement C3

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Complement Pathway, Alternative

Share to Glomerulonephritis

Share to Glomerulonephritis, Membranoproliferative

Share to Plant Extracts

Share to Receptors, Complement 3b

Source

Identifiers

PMID: 24799307
DOI: 10.1055/s-0034-1375299

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Treatment of C3 glomerulopathy with complement blockers.PMID 24799307Read ↗

C3 Glomerulopathy: A Current Perspective in an Evolving LandscapeSemantic proximity Read ↗

C3 glomerulopathy: a kidney disease mediated by alternative pathway deregulationSemantic proximity Read ↗

Complement and Complement Targeting Therapies in Glomerular DiseasesSemantic proximity Read ↗

Complement inhibition in C3 glomerulopathy.Semantic proximity Read ↗

Targeted Complement Treatments in Glomerulopathies: A Comprehensive ReviewSemantic proximity Read ↗

C3 glomerulopathy: what's in a name?Semantic proximity Read ↗

Recent insights into C3 glomerulopathySemantic proximity Read ↗

Evolving complexity of complement-related diseasesSemantic proximity Read ↗

Acquired and genetic determinants of disease phenotype and therapeutic strategies in C3 glomerulopathy and immunoglobulin-associated MPGNSemantic proximity Read ↗

C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up.Semantic proximity Read ↗

C3 glomerulopathy: the genetic and clinical findings in dense deposit disease and C3 glomerulonephritis.Semantic proximity Read ↗

Membranoproliferative glomerulonephritis: no longer the same disease and may need very different treatmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.